In older patients with inflammatory bowel disease, tumor necrosis factor alpha antagonist therapy and vedolizumab were found to be comparable with regard to both safety and effectiveness.
A greater number of early adverse life events as well as more severe traumatic experiences were found to be associated with an increased risk for developing irritable bowel syndrome.
The Company has already completed a Phase 1 trial of this synthetic glucagon-like peptide (GLP-2) analog.
Low vitamin D levels have been linked to multiple diseases including some cancers, neurologic disorders, decrease in bone density, and cognitive decline in the elderly, and research suggests that a possible inflammatory response in the gut when vitamin D levels are low may cause irritable bowel syndrome.
Loss to follow-up is common with inflammatory bowel disease, and both low C-reactive protein levels and long travel time to the hospital are predictors of follow-up loss
The test works by measuring levels of anti-cytolethal distending toxin B (CdtB) and anti-vinculin, 2 biomarkers of post-infectious IBS-D and IBS-M.
While several secretagogues have been recently approved by the Food and Drug Administration (FDA), a lack of head-to-head trials led researchers to conduct a systematic review to compare the effectiveness of these agents in patients with IBS-C.
As fecal microbiota transplantation has been found to be effective in treating a number of gastrointestinal diseases, such as Clostridium difficile infection, researchers are now assessing whether it may also be effective for patients with irritable bowel syndrome.
A 2-week course of treatment with rifaximin for diarrhea-predominant irritable bowel syndrome was found to improve abdominal pain symptoms.
Patients with irritable bowel syndrome found FODMAP more beneficial than general dietary advice
